Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12434789 | 0.82 | TP53 (0.48) | TP53TSHRALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL41991 | 0.81 | TTR (0.50) | TP53TSHRCYP3A4HSD17B10TDP1 | |
| SCHEMBL2281581 | 0.79 | PPARG (0.38) | TP53SLC6A2SLC6A3MRGPRX4 | |
| SCHEMBL4289243 | 0.77 | CYP3A4 (0.45) | TSHRALDH1A1CYP3A4LMNA | |
| SCHEMBL4469317 | 0.77 | SLC6A4 (0.37) | SLC6A2SLC6A3 | |
| SCHEMBL4474308 | 0.77 | MAPT (0.49) | ALDH1A1CYP3A4TDP1LMNACYP1A2 | |
| SCHEMBL262998 | 0.77 | HSD17B10 (0.50) | TSHRALDH1A1CYP3A4HSD17B10TDP1 | |
| SCHEMBL1745045 | 0.77 | HSD17B10 (0.48) | TSHRALDH1A1CYP3A4HSD17B10TDP1 | |
| SCHEMBL9488215 | 0.77 | RHEB (0.55) | TP53TSHRALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL3537469 | 0.76 | TRPV4 (0.47) | TP53TSHRALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211195-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
| CN-107406471-B | Heterocyclic compound and organic light-emitting element comprising same | 株式会社LG化学 | 2020-06-02 | — | — | CN | disclosed |
| EP-2183241-B1 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LTD (GB) | 2012-12-19 | — | — | EP | disclosed |
| US-8143307-B2 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-27 | — | — | US | disclosed |
| US-20120068123-A1 | USE OF PHTHALOCYANINE COMPOUNDS WITH ARYL OR HETARYL SUBSTITUENTS IN ORGANIC SOLAR CELLS | BASF SE (DE) | 2012-03-22 | — | — | US | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1399445-B9 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2010054260-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1189905-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6777406-B2 | SUCH AS PYRIDO(3,2,1-IJ)PYRROLO(3,4-C)QUINOLIN-8-ONE DERI-VATIVES; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040127482-A1 | Administering substituted heterocycle fused gamma-carboline compounds for therapy of addictive behavior associated with 5HT2C receptor modulation | ROBICHAUD ALBERT J (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040092502-A1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2004-05-13 | — | — | US | disclosed |
| US-20040062930-A1 | Electroactive polymers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| US-6548493-B1 | Serotonin receptor modulators (5-HT2C and 5-HT2A); treating obesity, anxiety, depression, psychological disorders, migraine, sexual disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| EP-1189905-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000077001-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | TP53 1765/4885TSHR 4868/4885ALDH1A1 2007/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | TP53 4664/4885TSHR 2806/4885ALDH1A1 1252/4885 |
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | TP53 1143/4885TSHR 4049/4885ALDH1A1 1326/4885 |
| US-20120068123-A1 | USE OF PHTHALOCYANINE COMPOUNDS WITH ARYL OR HETARYL SUBSTITUENTS IN ORGANIC SOLAR CELLS | RB1, NRAS, HLA-B | TP53 353/4885TSHR 3595/4885ALDH1A1 761/4885 |
| US-20040092502-A1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | HTR1B, HTR2B, HTR1A | TP53 4885/4885TSHR 450/4885ALDH1A1 2874/4885 |
| US-20040127482-A1 | Administering substituted heterocycle fused gamma-carboline compounds for therapy of addictive behavior associated with 5HT2C receptor modulation | HTR2C, HTR2B, HTR3B | TP53 4883/4885TSHR 384/4885ALDH1A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.